推动同防共治 男性九价HPV疫苗首批开打

Core Viewpoint - The recent approval of the nine-valent HPV vaccine for males aged 16-26 marks a significant advancement in the prevention of HPV-related cancers and diseases in China, promoting a new phase of gender-inclusive HPV prevention efforts [1] Group 1: HPV Vaccine Approval and Public Health Impact - The nine-valent HPV vaccine has received approval from the National Medical Products Administration for use in males aged 16-26, indicating a shift towards gender-inclusive HPV prevention strategies in China [1] - An academic conference themed "Gender-inclusive Prevention: Accelerating the Elimination of Cervical Cancer" was held, where experts discussed the role of the HPV gender-inclusive prevention plan in enhancing public health [1] Group 2: Male HPV Infection Rates and Awareness - HPV infection is a significant public health issue, with studies indicating that approximately 90% of men will be infected with HPV at least once in their lifetime, and the infection rate in males is higher than in females [2] - Continuous infection with high-risk HPV types can lead to increased risks of various cancers in men, including anal, penile, and oropharyngeal cancers, with 88% of anal cancers attributed to persistent HPV infection [2] Group 3: Vaccine Efficacy and Recommendations - Research confirms that the HPV vaccine provides long-lasting protection and has a good safety profile, with no breakthrough cases of vaccine-type genital warts, anal cancer, or serious adverse events reported over a 10-year follow-up [3] - Vaccination is highlighted as the best method for preventing cervical cancer and other HPV-related cancers, reducing the likelihood of infection and transmission among males [3] - There has been a notable increase in inquiries and appointments for the nine-valent HPV vaccine among eligible males since its approval, indicating growing public interest and awareness [3]